Sydney Jennings

Women with diabetes receive less contraception, cancer screening, and preconception care, increasing risk for preventable complications.

Study of 669 083 patients links antidepressants and some antidiarrheals to higher mortality in IBS, raising prescribing concerns.

Phase 3 data show an investigational 6-valent OspA-based Lyme vaccine prevents more than 70% of cases; regulatory submissions planned.

New AHA/ASA stroke guidance widens thrombolysis and EVT access, eases imaging, and updates BP/glucose targets—what frontline teams need now.

The algorithm adds a new diabetes classification pathway and expands comorbidity-driven pharmacotherapy guidance, incorporating recent trial data on GLP-1 receptor agonists, SGLT2 inhibitors, and MASLD.

Phase 3 data show oral PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at 8 weeks vs oral nonstatins in high-risk patients.

Phase 3b findings suggest that combining a GLP-1/GIP receptor agonist with IL-17 inhibition may improve both joint and metabolic outcomes in adults with psoriatic arthritis and obesity.

Your daily dose of the clinical news you may have missed.

The approval of Foundayo (orforglipron) marks a formulation milestone in obesity pharmacotherapy, offering a once-daily pill free of the fasting requirements that may complicate adherence.

From new oral options for for psoriatic disease to once-weekly insulin, 5 FDA decisions with implications for primary care practice.

Your daily dose of the clinical news you may have missed.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

Your daily dose of the clinical news you may have missed.

From oral GLP-1s for obesity and T2D to a potential first new smoking cessation drug in 20 years, here are 5 FDA pipeline updates to put on your radar.

The FDA has approved Awiqli® (insulin icodec-abae), the first once-weekly basal insulin for adults with type 2 diabetes, reducing injections from 7 to 1 per week.

New 4-year data from the ADlong trial show lebrikizumab achieved EASI-75 in 94% of atopic dermatitis patients on once-monthly maintenance dosing.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Your daily dose of the clinical news you may have missed.

COVID-19 infection increased risks of AKI, CKD, and ESRD vs influenza in a 3 million–patient US study, highlighting need for kidney monitoring.

New data to be presented at ACC 2026 shows 6 hours of daily screen time may lead to higher BP, LDL-C, BMI, and nicotine use, independent of exercise.

Your daily dose of the clinical news you may have missed.

Replacing 30 minutes of sedentary time with sleep or exercise was linked to lower insulin resistance in teens in preliminary AHA EPI 2026 data.

Test your knowledge of added sugar limits, processed food reduction, and label interpretation in the 2025–2030 Dietary Guidelines.

New FDA-approved semaglutide 7.2 mg shows ~21% weight loss, offering primary care clinicians a higher-efficacy obesity treatment option.

FDA clears MiniMed Flex insulin pump with smartphone control and adaptive algorithm for type 1 and insulin-requiring type 2 diabetes.

Test your knowledge of saturated fat thresholds, sodium limits, and alcohol recommendations in the 2025–2030 Dietary Guidelines.

ATTD 2026: Registry data from US primary care practices showed Dexcom G7 use lowered HbA1c by 0.7% over 1 year in adults with noninsulin-treated type 2 diabetes.

A COSMOS trial analysis found daily multivitamin use modestly slowed epigenetic markers of biological aging in older adults over 2 years.

A new study shows virtual physician apps replace about half of clinic visits for young adults, while the rest adds new, low-risk demand.